Promimic AB (publ)

Hej och välkomna till den här presentationen som ska handla om ProMimic första kvartalet 2024. Jag heter Magnus Larsson och är vd för bolaget.

Heidi Bader heter jag och är ekonomichef på ProMimic. Magnus, skulle du kunna berätta lite grann om vad som har hänt under det första kvartalet?

During the first quarter we have focused on investments, investments in future growth. We have moved here to GoCo Health Innovation City where we are today. We have invested in new laboratories, new offices. We have actually more than doubled our capacity to be able to do customer projects here at GoCo. It has also been a very exciting quarter when it comes to newly registered products with our technology. A total of nine products among our customers have been registered for approval on the American market and FDA. And that is actually a record for a quarter.

Yes, it feels incredibly good to be here. But you, this with the FDA approval, what is so important to them for us?

It is the driving force in our future growth. It is our customers' products when they are approved and then put on the market. It is what gives us royalty revenues and future growth, so it is important to us.

Very interesting. Is there anything that has not gone according to expectations?

Yes, we can note that one of our customers has had some disturbances in his supply chain, which has affected us negatively. The problems are now solved and we do not see that they will affect us in the future.

Yes, both are good for the future. What are the other expansion plans like?

We have also invested in our facility in the USA, where we process our customer products in Warsaw, Indiana. We have made purchases and are mounting two new production lines. They are being tested this summer and will be in use sometime during quarter three this year. Could you tell us a little bit about the figures?

Yes, of course. We have just finished two fantastic years, and that has lifted us to a new level. During the first quarter of 2024, we will convert SEK 8.7 million, which is 40% growth compared to previous years. Our royalty and license revenues go up to SEK 4 million, which is 79% growth. And then we have our turnover for these deductions, which goes up to SEK 2.5 million, which is completely in line with the plan. How would you like to summarize the first quarter?

Yes, as I started by saying that it has been a quarter that has focused on investments for future growth, both in new locations here in Sweden and in the USA. And not least also the new products that have been approved by FDA, which our customers will introduce during the rest of the year.

And with that I think we end this conversation and I would like to thank everyone who has listened.

Thanks a lot.